American Bio Medica wins legal round in patent dispute
This article was originally published in Clinica
American Bio Medica has won the latest round in its patent litigation with Phamatech concerning urine-based drug-of-abuse testing kits in the US. The Delaware district court has denied Phamatech's request to throw out American Bio Medica's patent infringement case against Phamatech and other defendants. The trial has also been moved to California, the home state of Phamatech.
You may also be interested in...
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.